(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Brand names, (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Analogs
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Brand Names Mixture
- No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Chemical_Formula
C20H30O2
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid RX_link
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid fda sheet
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid msds (material safety sheet)
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Synthesis Reference
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Molecular Weight
302.456 g/mol
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Melting Point
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid H2O Solubility
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid State
Oily Liquid
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid LogP
6.23 +/- 0.48
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Dosage Forms
Capsule (usually in fish oil in a combination with DHA)
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Indication
EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Pharmacology
Eicosanoids are chemical messengers derived from 20-carbon polyunsaturated fatty acids that play critical roles in immune and inflammatory responses. Both 20-carbon omega-6 fatty acids (arachidonic acid) and 20-carbon omega-3 fatty acids (EPA) can be found in cell membranes. During an inflammatory response, arachidonic acid and EPA are metabolized by enzymes known as cyclooxygenases and lipoxygenases to form eicosanoids. Increasing omega-3 fatty acid intake increases the EPA content of cell membranes and decreases the arachidonic acid content, resulting in higher proportions of eicosanoids derived from EPA. Physiologic responses to arachidonic acid-derived eicosanoids differ from responses to EPA-derived eicosanoids. In general, eicosanoids derived from EPA are less potent inducers of inflammation, blood vessel constriction, and clotting than eicosanoids derived from arachidonic acid.
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Absorption
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid side effects and Toxicity
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Patient Information
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid Organisms Affected
No information avaliable
